Registry of Sustained Immunity to COVID-19 Among ESKD Patients
RePAiR
1 other identifier
observational
2,315
1 country
12
Brief Summary
This is a multi-center, prospective registry study of subjects undergoing hemodialysis for treatment of end-stage renal disease in a DaVita center. The objective of this study is to understand whether and to what degree anti-SARS-CoV-2 antibodies mitigate the risk of subsequent SARS-CoV-2 infection and COVID disease within the ESKD population.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2020
Shorter than P25 for all trials
12 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 20, 2020
CompletedFirst Submitted
Initial submission to the registry
July 22, 2020
CompletedFirst Posted
Study publicly available on registry
August 3, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 12, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
February 12, 2021
CompletedMay 27, 2021
May 1, 2021
7 months
July 22, 2020
May 26, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Anti-SARS-CoV-2 antibodies
Through study completion (5 visits), an average of 6 months
Incidence and severity of COVID-19
Through study completion (5 visits), an average of 6 months
Eligibility Criteria
1. Between ≥18 and 80 years of age, inclusive. 2. Ability to provide informed consent. 3. Currently receiving hemodialysis treatment for end-stage kidney disease at a DaVita dialysis center.
You may qualify if:
- Between ≥18 and 80 years of age, inclusive.
- Ability to provide informed consent.
- Currently receiving hemodialysis treatment for end-stage kidney disease at a DaVita dialysis center.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (12)
DCR Victorville
Victorville, California, 92394, United States
DCR Connecticut
Bridgeport, Connecticut, 06606, United States
DCR Twin Cities
Minneapolis, Minnesota, 55404, United States
DCR Las Vegas
Las Vegas, Nevada, 89128, United States
DCR Bronx
The Bronx, New York, 10461, United States
DCR Canton
Canton, Ohio, 44718, United States
DCR El Paso
El Paso, Texas, 79925, United States
DCR Lewisville
Lewisville, Texas, 75057, United States
DCR San Antonio
San Antonio, Texas, 78215, United States
DCR San Antonio
San Antonio, Texas, 78230, United States
DCR Norfolk
Norfolk, Virginia, 23502, United States
DCR Milwaukee
Milwaukee, Wisconsin, 53226, United States
Biospecimen
Baseline serologic characterization for anti-SARS-CoV-2 IgM and IgG
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Francesca Tentori, MD
Davita Clinical Research
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 22, 2020
First Posted
August 3, 2020
Study Start
July 20, 2020
Primary Completion
February 12, 2021
Study Completion
February 12, 2021
Last Updated
May 27, 2021
Record last verified: 2021-05